ProPhase Labs PRPH Stock
ProPhase Labs Price Chart
ProPhase Labs PRPH Financial and Trading Overview
| ProPhase Labs stock price | 0.62 USD |
| Previous Close | 0.37 USD |
| Open | 0.37 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.35 - 0.39 USD |
| 52 Week Range | 0.22 - 3.37 USD |
| Volume | 739.75K USD |
| Avg. Volume | 2.21M USD |
| Market Cap | 15.18M USD |
| Beta (5Y Monthly) | -0.415 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.8 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 24, 2022 |
| 1y Target Est | 13.8 USD |
PRPH Valuation Measures
| Enterprise Value | 30.17M USD |
| Trailing P/E | N/A |
| Forward P/E | 0.7610417 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.596236 |
| Price/Book (mrq) | 1.0035714 |
| Enterprise Value/Revenue | 5.162 |
| Enterprise Value/EBITDA | -1.055 |
Trading Information
ProPhase Labs Stock Price History
| Beta (5Y Monthly) | -0.415 |
| 52-Week Change | -88.10% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 3.37 USD |
| 52 Week Low | 0.22 USD |
| 50-Day Moving Average | 0.36 USD |
| 200-Day Moving Average | 0.73 USD |
PRPH Share Statistics
| Avg. Volume (3 month) | 2.21M USD |
| Avg. Daily Volume (10-Days) | 596.67K USD |
| Shares Outstanding | 41.54M |
| Float | 38.22M |
| Short Ratio | 0.09 |
| % Held by Insiders | 7.99% |
| % Held by Institutions | 12.14% |
| Shares Short | 156.14K |
| Short % of Float | 0.41% |
| Short % of Shares Outstanding | 0.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -255.97% |
| Gross Margin | 7.45% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.91% |
| Return on Equity (ttm) | -162.30% |
Income Statement
| Revenue (ttm) | 5.85M USD |
| Revenue Per Share (ttm) | 0.24 USD |
| Quarterly Revenue Growth (yoy) | -39.30% |
| Gross Profit (ttm) | 436K USD |
| EBITDA | -28597000 USD |
| Net Income Avi to Common (ttm) | -48679000 USD |
| Diluted EPS (ttm) | -2.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 88K USD |
| Total Cash Per Share (mrq) | 0.002 USD |
| Total Debt (mrq) | 14.01M USD |
| Total Debt/Equity (mrq) | 92.65 USD |
| Current Ratio (mrq) | 1.03 |
| Book Value Per Share (mrq) | 0.364 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15779000 USD |
| Levered Free Cash Flow (ttm) | 5.61M USD |
Profile of ProPhase Labs
| Country | United States |
| State | NY |
| City | Garden City |
| Address | 711 Stewart Avenue |
| ZIP | 11530 |
| Phone | 215 345 0919 |
| Website | https://www.prophaselabs.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 96 |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Q&A For ProPhase Labs Stock
What is a current PRPH stock price?
ProPhase Labs PRPH stock price today per share is 0.62 USD.
How to purchase ProPhase Labs stock?
You can buy PRPH shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ProPhase Labs?
The stock symbol or ticker of ProPhase Labs is PRPH.
Which industry does the ProPhase Labs company belong to?
The ProPhase Labs industry is Diagnostics & Research.
How many shares does ProPhase Labs have in circulation?
The max supply of ProPhase Labs shares is 4.19M.
What is ProPhase Labs Price to Earnings Ratio (PE Ratio)?
ProPhase Labs PE Ratio is now.
What was ProPhase Labs earnings per share over the trailing 12 months (TTM)?
ProPhase Labs EPS is -19.8 USD over the trailing 12 months.
Which sector does the ProPhase Labs company belong to?
The ProPhase Labs sector is Healthcare.
ProPhase Labs PRPH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23613.31 USD — |
+0.22
|
3.5B USD — | 23527.97 USD — | 23621.72 USD — | — - | 3.5B USD — |
| US Tech Capital Market Composite RCMP | 133.06 USD — |
+0.23
|
— — | 131.86 USD — | 133.42 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29035.82 USD — |
+0.22
|
— — | 28930.89 USD — | 29046.16 USD — | — - | — — |
- {{ link.label }} {{link}}


